Local Treatment of Inflammatory Joint Diseases Benefits and Risks
This book presents a systematic survey of different local treatments in inflammatory joint diseases and their potential side effects and complications. Both surgical therapies and pharmaceutical strategies involving local or systemic application of anti-i
- PDF / 5,001,797 Bytes
- 147 Pages / 439.43 x 683.15 pts Page_size
- 13 Downloads / 200 Views
123
Local Treatment of Inflammatory Joint Diseases
Willm Uwe Kampen • Manfred Fischer Editors
Local Treatment of Inflammatory Joint Diseases Benefits and Risks
Editors Willm Uwe Kampen Nuklearmedizin Spitalerhof Hamburg, Germany
Manfred Fischer Kassel, Germany
ISBN 978-3-319-16948-4 ISBN 978-3-319-16949-1 DOI 10.1007/978-3-319-16949-1
(eBook)
Library of Congress Control Number: 2015939682 Springer Cham Heidelberg New York Dordrecht London © Springer International Publishing Switzerland 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)
Preface
More than 60 years ago, in 1952, Fellinger and Schmid published data about intraarticular administration of either 3.7–7.4 MBq 131I or 37 MBq 198Au. They observed a significant reduction of pain in patients suffering from rheumatoid arthritis (1). Today three radionuclides are approved and/or sold in many countries (Table 1) for treatment of inflammatory joint diseases. The aim of radiosynovectomy is to decrease swelling, pain, stiffness and joint effusion to improve joint function by treating inflammation of synovial tissue using β-emitting radiocolloids. Although many studies have proven its therapeutic efficacy and safety and many thousands of successful treatments are done by experienced nuclear medicine physicians, assuming both a responsible and proper patient selection and a skilful injection technique, there is still a controversial discussion about its benefits and risks. In patients suffering from inflammatory joint diseases, synovium shows thickening of the lining layer, increased vascularity and inflammatory cell infiltration Table 1 Approval and Disposal of radionclides used for radiosynovectomy 90
Country Germany France Switzerland Portugal Belgium Netherlands Luxembourg Greece Norway Irland Turkey Czech Rep. Mexico Approval vs. sales
Yttrium Approval x x x x x x x x x
Data Loading...
